Published • loading... • Updated
Merck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term Headwinds
Summary by 247wallst.com
1 Articles
1 Articles
Merck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term Headwinds
The post Merck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term Headwinds appeared first on 24/7 Wall St.. Quick Read Merck (MRK) reported Q1 2026 revenue of $16.29B, up 4.87% year-over-year and beating consensus estimates, with KEYTRUDA sales jumping 12% to $8.03B and WINREVAIR surging 88% to $525M despite a $9.0B acquisition charge from the Cidara deal. Merck’s deep Phase 3 oncology pipeline with near-term catalysts …
·New York, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
